BACKGROUND: In @entity1 with type-2 @entity6 receiving @entity1697 ( @entity1697 ), the addition of @entity2690 is frequently required to achieve sufficient control over blood @entity413 levels. It is, however, difficult to predict if, when and in which @entity1 @entity2690 therapy will be needed. We aimed to identify @entity1 related variables associated with the addition of basal @entity2690 to oral therapy resulting in a basal supported oral therapy (BOT). METHODS: DIVE ( @entity6 Versorgungs-Evaluation) is a prospective, observational, multi-centre @entity6 registry established in Germany in 2011. For the present explorative analysis, 31,008 @entity1 with type-2 @entity6 prescribed at least one OAD were included. @entity1 who had previously received @entity2690 and those over 90  years old were excluded. The event of interest was defined as the initiation of BOT during the observational period. Cause-specific Cox proportional hazards models based on a competing risk framework were applied for risk quantification. RESULTS: Multivariable adjusted hazard ratios demonstrated that longer @entity6 duration, higher BMI, poorer glycaemic control, documentation of any micro- or macrovascular comorbidity, the presence of concomitant non-antidiabetic pharmacotherapies, and greater numbers of prescribed @entity1697 increased the likelihood of BOT initiation. On the other hand BOT initiation was less likely in @entity1 with older age and female gender. Analysing the likelihood of OAD termination without initiation of BOT provided supportive evidence for the variables predictive of BOT initiation. DISCUSSION: Analysis of the DIVE registry has resulted in the identification of a number of factors that may be predictive for the initiation of BOT for type-2 @entity6 @entity1 initially prescribed one or more @entity1697 . Poor glycaemic control, the presence of vascular comorbidities and concomitant medications, and a greater number of @entity1697 were all detected to increase the risk of a switch to BOT. Female gender and younger age showed protective properties. CONCLUSIONS: The close monitoring of @entity1 displaying these characteristics may help to identify individuals who might benefit from early addition of @entity2690 therapy to their oral treatment regimen.

Treatment intensification using long-acting XXXX -predictors of future basal @entity2690 supported oral therapy in the DIVE registry.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1697 :: ('MESH:D009062', 'Disease') :: ['oral antidiabetic drugs', 'OADs'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'DIabetes'] @entity2690 :: ('3630', 'Gene') :: ['insulin'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity2690 :: (3630,Gene) :: ['insulin']
